Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
Monte Rosa Therapeutics Announces Leadership Team Promotions
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160
Monte Rosa Therapeutics CEO Markus Warmuth expects molecular glues to make up a new class of drugs with “almost unlimited potential” in the long run, allowing scientists to tackle disease-causing proteins considered out of reach.